Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Capecitabine × 30 days × Clear all

Phase

Phase 3 27 Phase 2 23 Phase 1/2 5 Phase 1 5 Phase NA 1 Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

HER2-positive Breast Cancer 1

Interventions

Cisplatin 12 Magnetic Resonance Spectroscopy 11 Specimen Handling 10 Carboplatin 9 Doxorubicin 8 pembrolizumab 7 Nivolumab 7 Gemcitabine 6 Bevacizumab 6 atezolizumab 5 Radiotherapy 5 Radiation 5 Platinum 5 Paclitaxel 5 Ipilimumab 5 1,2-diaminocyclohexaneplatinum II citrate 5 venetoclax 4 Pemetrexed 4 Immunoglobulin G 4 Disulfides 4 Biopsy 4 Taxes 3 Rituximab 3 Radiotherapy, Intensity-Modulated 3 Oxaliplatin 3 Docetaxel 3 Dexamethasone 3 Cyclophosphamide 3 CTLA-4 Antigen 3 Azacitidine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07413939 2026-03-10

BREnnA

Hoffmann-La Roche

Phase 2/3 Not yet recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡